Sinclair Research Announces Successful Validation of GLP Ototoxicity Testing Services
Sinclair Research, a leading provider of nonclinical contract research services, today announced completion of successful validation of GLP ototoxicity testing services in partnership with Turner Scientific, an industry leader specializing in nonclinical hearing research.
Sinclair Research, a leading provider of nonclinical contract research services, today announced completion of successful validation of GLP ototoxicity testing services in partnership with Turner Scientific, an industry leader specializing in nonclinical hearing research.
“Sinclair’s validated GLP ototoxicity testing services provide drug developers with more research options,” Andy Brown, Sinclair Research’s Vice President of Commercial Operations said. “As a result of our partnership with Turner Scientific, Sinclair Research is one of the only CROs that can offer GLP auditory safety research services, and we are excited to offer GLP ototoxicity testing along with IND-enabling nonclinical toxicology services at a single-site CRO.”
The partnership with Turner Scientific allows Sinclair Research to help drug developers effectively evaluate the risks of potential auditory damage prior to first-in-human trials, and will help safeguard developers from potential risk while also helping them get their products to market faster and safer than before.
Ototoxicity studies evaluate the safety and potential adverse effects a compound or device has on the inner ear and auditory nerves, which can lead to symptoms including dizziness, vertigo, tinnitus and hearing loss.
The partnership also allows both companies to provide experimental toxicology and efficacy services in auditory research for novel biopharmaceuticals and cell and gene therapies.
“Working together with Sinclair Research combines our more than 20 years of conducting auditory research with Sinclair’s experience in conducting quality nonclinical research,” Turner Scientific’s Chief Scientific Officer Dr. Jeremy Turner said. “These successful validation studies provided accurate, high-confidence data and conclusively demonstrated the high-quality auditory research support that Turner Scientific and Sinclair Research are able to provide drug developers.”
About Sinclair Research:
Sinclair Research, a mid-sized nonclinical contract research organization (CRO), offers animal efficacy models, pharmacokinetics/pharmacodynamics evaluation, IND-enabling toxicology and safety pharmacology research capabilities to support biopharmaceutical, animal health and medical device development programs. Sinclair is experienced in a wide range of therapeutic modalities, routes of administration and research models. With more than 50 years of experience, Sinclair is the undisputed expert in miniature swine studies and has emerged as a leader in diabetes, dermal, otic and animal health research services with streamlined quality systems supporting both VICH and GLP-compliant studies and SEND reporting with no backlog.
About Turner Scientific:
Turner Scientific, a leading preclinical contract research organization specializing in hearing research, provides non-GLP and GLP research services to advance sponsor compounds and devices toward IND/IDE approval and clinical trials. Turner Scientific serves a wide variety of biotechnology companies and pharmaceutical sponsors by evaluating therapeutic efficacy of new compounds, and by assessing the potential for ototoxicity, hearing loss, development of tinnitus, and balance/vestibular disorders. Turner Scientific provides niche expertise, unmatched study design and execution, data analysis, specialty report writing, and sponsor communication by hearing research experts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005561/en/